Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Homologous Recombination Deficiency (HRD)”

55 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 55 results

Testing effectiveness (Phase 2)Ended earlyNCT06964165
What this trial is testing

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 36
Not applicableUnknownNCT05044091
What this trial is testing

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Who this might be right for
Ovarian CancerHRDPARP Inhibitor
Xiaoxiang Chen 100
Testing effectiveness (Phase 2)UnknownNCT04983745
What this trial is testing

Niraparib and Dostarlimab in HRD Solid Tumors

Who this might be right for
Homologous Recombination Deficient Solid Tumors
West Cancer Center 30
Large-scale testing (Phase 3)Active Not RecruitingNCT02655016
What this trial is testing

Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 733
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Testing effectiveness (Phase 2)WithdrawnNCT06365970
What this trial is testing

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Who this might be right for
MMR-D/MSI-H Colorectal Cancers
Ibrahim Halil Sahin
Testing effectiveness (Phase 2)Study completedNCT01482715
What this trial is testing

Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer+1 more
pharmaand GmbH 136
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07113964
What this trial is testing

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

Who this might be right for
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
The First Affiliated Hospital with Nanjing Medical University 79
Testing effectiveness (Phase 2)Ended earlyNCT03367689
What this trial is testing

A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent

Who this might be right for
Breast Cancer
MedSIR 7
Testing effectiveness (Phase 2)Ended earlyNCT03875313
What this trial is testing

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast Cancer+4 more
Calithera Biosciences, Inc 33
Testing effectiveness (Phase 2)Study completedNCT04123366
What this trial is testing

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Who this might be right for
Solid Tumors
Merck Sharp & Dohme LLC 333
Testing effectiveness (Phase 2)Looking for participantsNCT07033819
What this trial is testing

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Who this might be right for
Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 48
Testing effectiveness (Phase 2)WithdrawnNCT03432676
What this trial is testing

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Who this might be right for
ATM Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+7 more
M.D. Anderson Cancer Center
Not applicableNot Yet RecruitingNCT07825181
What this trial is testing

Homologous Recombination Repair Deficiency (HRD) Testing in Newly Diagnosed Advanced-stage Epithelial Ovarian Cancer in Italy

Who this might be right for
Epithelial Ovarian Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1,125
Testing effectiveness (Phase 2)Active Not RecruitingNCT03742895
What this trial is testing

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Who this might be right for
Advanced Solid Neoplasms
Merck Sharp & Dohme LLC 329
Testing effectiveness (Phase 2)Looking for participantsNCT06152731
What this trial is testing

HRD Tests for Ovarian cancER

Who this might be right for
Ovarian Cancer
Centre Francois Baclesse 88
Testing effectiveness (Phase 2)UnknownNCT03337087
What this trial is testing

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Who this might be right for
Metastatic Biliary Tract CarcinomaMetastatic Colorectal CarcinomaMetastatic Gastroesophageal Junction Adenocarcinoma+6 more
Academic and Community Cancer Research United 18
Not applicableUnknownNCT06242392
What this trial is testing

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Fujian Cancer Hospital 250
Testing effectiveness (Phase 2)Study completedNCT02952534
What this trial is testing

Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 277
Early research (Phase 1)Looking for participantsNCT06856499
What this trial is testing

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Who this might be right for
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
University of Colorado, Denver 50
Next Page